Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients
With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)